Did Hancock SAGE NHS Cause 60K UK Deaths? (Dr Tess Lawrie)

Tony Gosling with Dr Tess Lawrie, Director, The Evidence-Based Medicine Consultancy Ltd

Tess Lawrie

Dr Tess Lawrie (MBBCh, DFSRH, PhD), as director of E-BMC Ltd, is committed to improving the quality of healthcare through rigorous research. Her range of research expertise, based on research experience in both developing and developed countries, uniquely positions her to evaluate and design research for a variety of healthcare settings. Tess is a frequent member of technical teams responsible for developing international guidelines.

The Evidence-Based Medicine Consultancy Ltd - https://www.e-bmc.co.uk​

This video is approximately 43 minutes.

2 Likes

The fact that Ivermectin existed would have blocked their Emergency Use Protocols:

It's obvious T.H.E.Y. had to go into over-drive to discredit Ivermectin, because they would not have gotten their "emergency use" go-ahead if something was already on the market to treat it. The propaganda and cover up continues. If they weren't able to block Ivermectin's use, then they couldn't force through their vaccination programme.

Under an EUA, FDA may allow the use of unapproved medical products, or unapproved uses of approved medical products in an emergency to diagnose, treat, or prevent serious or life-threatening diseases or conditions when certain statutory criteria have been met, including that there are no adequate, approved, and available alternatives. Emergency Use Authorization for Vaccines Explained | FDA

Why was the MHRA able to give an EUA faster than US FDA or EMA? According to the MHRA, they undertook a rolling review of the data since the first data was made available in October 2020 to allow for the assessment of the vaccine in the shortest possible time...

National Regulatory Authorities (NRAs) can issue an EUA when certain legal criteria have been met such as a national health emergency and/or no adequate, approved, and available alternatives.

The authorisation recently announced in the United Kingdom under Regulation 174 is temporary and only relates to a limited number of specific batches of the Covid-19 vaccine BNT162b2 supplied by Pfizer and BioNTech, in response to the increased spread of Covid-19 and deaths in the UK. This emergency approval is not a market authorisation and there is no general authorisation to place this vaccine on the market in the UK. However, the conditions of the EUA stipulate that the sponsor “must operate a comprehensive pharmacovigilance (safety monitoring) system for this product in accordance with UK legislation for licensed products, as if they were market authorisation holders.” This clause ensures that processes are in place to monitor changes in the benefit-risk profile of the vaccine, and facilitate timely revisions to its use if required. Making Sense of Emergency Use Authorisations (EUAs) for Covid-19 Vaccines and Considerations for the Road Ahead

EMA is accepting rolling submissions for Covid-19 vaccines under the conditional marketing authorisation (CMA) procedures and is expected to announce a decision on the Pfizer/BioNtech vaccine after its scientific committee for human medicines meets on 29 December 2020. EMA can grant CMA for such health products where “the benefit of immediate availability outweighs the risk of less comprehensive data than normally required, based on the scope and criteria defined in legislation and guidelines.

Vaccinating the UK: how the covid vaccine was approved, and other questions answered

We keep hearing this phrase - "benefits outweigh the risks" - is this to keep the vaccine programme going?